El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
Zentalis Pharmaceuticals Inc
Cerrado
2.73 1.11
Resumen
Variación precio
24h
Mínimo
2.63
Máximo
2.73
Ingresos | 183K -27M |
|---|---|
Empleados | 166 |
EBITDA | 9.4M -27M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +158.3% upside |
Próximas Ganancias | 24 mar 2026 |
|---|
Capitalización de Mercado | 80M 175M |
|---|---|
Apertura anterior | 1.62 |
Cierre anterior | 2.73 |
Puntuación técnica
By Trading Central
Confianza
Very Strong Bearish Evidence
Zentalis Pharmaceuticals Inc Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Zentalis Pharmaceuticals Inc Esperado
Precio Objetivo
By TipRanks
158.3% repunte
Estimación a 12 meses
Media 7 USD 158.3%
Máximo 10 USD
Mínimo 4 USD
De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zentalis Pharmaceuticals Inc Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Live chat